This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the
study participants will receive ruxolitinib for approximately 15 days, and the other half
will receive a placebo (sugar pill) for approximately 15 days. Once study participants have
completed their ruxolitinib or placebo, participants will undergo surgery to remove the
premalignant breast tissue.
Phase:
Phase 2
Details
Lead Sponsor:
Julie Nangia
Collaborators:
Incyte Corporation Translational Breast Cancer Research Consortium